A recent article published in Science translational Medicine by Spector et al. set out to determine the contribution of fundamental research to the generation of new medicines. By tracking the scientific origins of some of today’s most “transforming” FDA-approved drugs, including medicines such as TNF blockers, ACE inhibitors, kinase inhibitors and others, they find that approximately 80% of the 28 medicines studied, originated as basic research discoveries by scientist seeking to understand a biological process or disease. It is noteworthy, that the path to drug discovery that starts with basic scientific research more often than not includes fundamental research work performed in mouse models of disease that provide invaluable insights and proof of concept on in vivo disease mechanisms and drug activity. One such example of the invaluable contribution of animal disease models in the path to drug discovery, is the human TNF transgenic Tg197 arthritis mouse model that in 1991 provided the first in vivoevidence that deregulated TNF production was causal to chronic polyarthritis (Keffer et al.).


Specialised phenotyping
INFRAFRONTIER2020 project – Trans-national Access call for proposals
April 2019

Call information and application forms


Context and aims of the call

The INFRAFRONTIER mouse clinics offer the examination of mouse mutants using a broad and standardised phenotypic check-up covering key research areas such as behaviour, clinical chemistry, immunology, energy metabolism, and lung function amongst others. If phenotypes are uncovered by the primary assays, mouse mutants can be subjected to more detailed analyses in hypothesis driven and disease focussed phenotyping pipelines. Read More

Biomedcode’ s R&D team participated in the activities of the 1st  BSRC Al. Fleming Retreat. R&D projects were presented in three posters and scientific results were discussed with BSRC Al. Fleming scientists. Biomedcode’s overall activities were presented in a regular talk. Read More